par Baselga, José;Campone, Mario;Piccart-Gebhart, Martine 
;Burris, Howard A;Rugo, Hope;Sahmoud, Tarek;Noguchi, S;Gnant, Michael;Pritchard, Kathleen;Lebrun, Fabienne;Beck, J Thaddeus;Ito, Y;Yardley, Denise A;Deleu, I;Perez, Alejandra;Bachelot, Thomas;Vittori, Luc;Xu, Z.;Mukhopadhyay, Pabak;Lebwohl, David;Hortobagyi, Gabriel N.
Référence The New England journal of medicine, 366, 6, page (520-529)
Publication Publié, 2012-02
;Burris, Howard A;Rugo, Hope;Sahmoud, Tarek;Noguchi, S;Gnant, Michael;Pritchard, Kathleen;Lebrun, Fabienne;Beck, J Thaddeus;Ito, Y;Yardley, Denise A;Deleu, I;Perez, Alejandra;Bachelot, Thomas;Vittori, Luc;Xu, Z.;Mukhopadhyay, Pabak;Lebwohl, David;Hortobagyi, Gabriel N.Référence The New England journal of medicine, 366, 6, page (520-529)
Publication Publié, 2012-02
Article révisé par les pairs
| Résumé : | Resistance to endocrine therapy in breast cancer is associated with activation of the mammalian target of rapamycin (mTOR) intracellular signaling pathway. In early studies, the mTOR inhibitor everolimus added to endocrine therapy showed antitumor activity. |
